QVA149 (indacaterol/glycopyrronium fixed-dose combination): A review of its use in patients with chronic obstructive pulmonary disease

Drugs

Volumn 74, Issue 4, 2014, Pages 465-488

  Frampton, James E ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; FLUTICASONE PROPIONATE PLUS SALMETEROL; GLYCOPYRRONIUM BROMIDE; GLYCOPYRRONIUM BROMIDE PLUS INDACATEROL; INDACATEROL; MUSCARINIC RECEPTOR BLOCKING AGENT; PLACEBO; QVA 149; TIOTROPIUM BROMIDE; UNCLASSIFIED DRUG; BRONCHODILATING AGENT; INDAN DERIVATIVE; QUINOLONE DERIVATIVE;

AREA UNDER THE CURVE; CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG TOLERABILITY; DRUG USE; DYSPNEA; EUROPEAN UNION; EXERCISE TOLERANCE; FORCED EXPIRATORY VOLUME; HEALTH STATUS; HEART RATE; HUMAN; JAPAN; LONG TERM CARE; LUNG FUNCTION; MAXIMUM PLASMA CONCENTRATION; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW; SLEEP AROUSAL DISORDER; SMOOTH MUSCLE RELAXATION; ST. GEORGE RESPIRATORY QUESTIONNAIRE; STEADY STATE; ANALOGS AND DERIVATIVES; INHALATIONAL DRUG ADMINISTRATION; LUNG FUNCTION TEST; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

ADMINISTRATION, INHALATION; BRONCHODILATOR AGENTS; CLINICAL TRIALS, PHASE III AS TOPIC; GLYCOPYRROLATE; HUMANS; INDANS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUINOLONES; RESPIRATORY FUNCTION TESTS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84897109639     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.1007/s40265-014-0194-8     Document Type: Review

References (100)

1. McKeage K. Indacaterol: a review of its use as maintenance therapy in patients with chronic obstructive pulmonary disease. Drugs. 2012;72(4):543-63.
2. Carter NJ. Inhaled glycopyrronium bromide: a review of its use in patients with moderate to severe chronic obstructive pulmonary disease. Drugs. 2013;73(7):741-53.
3. Novartis. Novartis first-in-class once-daily dual bronchodilator Ultibro Breezhaler (QVA149) achieves near simultaneous approval for COPD patients in Europe and Japan [media release]. 23 Sep 2013. http://www.novartis.com/newsroom/ media-releases/en/2013/1730580.shtml.
4. Novartis Pharma K.K. Ultibro inhalation capsules: Japanese prescribing information. 2013. http://product.novartis.co.jp/ult/pi/ULT1309-03.pdf. Accessed 31 Jan 2014.
5. Novartis Europharm Ltd. Ultibro Breezhaler 85 micrograms/43 micrograms, inhalation powder hard capsules: EU summary of product characteristics. 2013. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR---Product-Information/ human/002679/WC500151255.pdf. Accessed 13 Nov 2013.
6. Dahl R, Dalal J, Alagappan VKT, et al. Efficacy and safety of QVA149 compared to the concurrent administration of its monocomponents indacaterol and glycopyrronium: the BEACON study. Int J COPD. 2013;8:501-8.
7. Donohue JF, Fogarty C, Lötvall J, et al. Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium. Am J Respir Crit Care Med. 2010;182(2):155-62.
8. 2-agonist indacaterol versus twice-daily formoterol in COPD. Thorax. 2010;65(6):473-9.
9. Feldman G, SilerT, Prasad N, et al. Efficacy and safety of indacaterol 150 μg once-daily in COPD: a double-blind, randomized, 12-week study. BMC Pulm Med. 2010. doi:10.1186/1471-2466-10-11.
10. Kornmann O, Dahl R, Centanni S, et al. Once-daily indacaterol versus twice-daily salmeterol for COPD: a placebo-controlled comparison. Eur Respir J. 2011;37(2):273-9.
11. Korn S, Kerwin E, Atis S, et al. Indacaterol once daily provides superior efficacy to salmeterol twice daily in COPD: a 12-week study. Respir Med. 2011;105(5):719-26.
12. Buhl R, Dunn LJ, Disdier C, et al. Blinded 12-week comparison of once-daily indacaterol and tiotropium in COPD. Eur Respir J. 2011;38(4):797-803.
13. DeCramer ML, Chapman KR, Dahl R, et al. Once-daily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease (INVIGORATE): a randomised, blinded, par-allel- group study. Lancet Respir Med. 2013;1(7):524-33.
14. 2-agonist, in subjects with COPD: a randomized, placebo-controlled study. Chest. 2011;140(1):68-75.
15. Pascoe S, Reynolds C, Pleskow W, et al. Safety, tolerability and pharmacokinetics of single escalating doses of indacaterol, a once-daily beta2-agonist bronchodilator, in subjects with COPD. Int J Clin Pharmacol Ther. 2011;49(2):153-61.
16. Sykes DA, Dowling MR, Leighton-Davies J, et al. The influence of receptor kinetics on the onset and duration of action and the therapeutic index of NVA237 and tiotropium. J Pharmacol Exp Ther. 2012;343(2):520-8.
17. D'Urzo A, Ferguson GT, van Noord JA, et al. Efficacy and safety of once-daily NVA237 in patients with moderate-to-severe COPD: the GLOW1 trial. Respir Res. 2011. doi:10.1186/1465-9921-12-156.
18. Kerwin E, Hébert J, Gallagher N, et al. Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 study. Eur Respir J. 2012;40(5):1106-14.
19. Drollmann A, Brown M, Sechaud R, et al. Effect of once-daily QVA149 on cardiac safety in healthy volunteers [abstract no. F64]. American Thoracic Society 109th international conference; 17-22 May 2013; Philadelphia (PA).
20. Van de Maele B, Fabbri LM, Martin C, et al. Cardiovascular safety of QVA149, a combination of indacaterol and NVA237. COPD patients. COPD. 2010;7(6):418-27.
21. Cazzola M, Calzetta L, Page CP, et al. Use of indacaterol for the treatment of COPD: a pharmacokinetic evaluation. Expert Opin Drug Metab Toxicol. 2014;10(1):129-37.
22. European Medicines Agency, Committee for Medicinal Products for Human Use (CHMP). CHMP assessment report: Ultibro Breezhaler. International non-proprietary names: indacaterol /glycopyrronium bromide. 2013. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR---Public-assessment- report/human/002679/WC500151257.pdf. Accessed 14 Nov 2013.
23. Asai K, Minakata Y, Hirata K, et al. Once-daily QVA149 is safe and well tolerated and improves lung function and health status in Japanese patients with COPD: the ARISE study [poster]. European Respiratory Society 23rd Annual Congress; 7-11 Sep 2013; Barcelona.
24. Novartis Pharmaceuticals. Long term safety and tolerability of QVA149 versus tiotropium in Japanese patients with chronic obstructive pulmonary disease (COPD) (ARISE) [ClinicalTrials. gov identifier NCT01285492]. US National Institutes of Health, ClinicalTrials.gov [online]. 2013. http://clinicaltrials. gov/show/NCT01285492. Accessed 9 Oct 2013.
25. Mahler DA, Decramer M, D'Urzo A, et al. Dual bronchodilation with QVA149 reduces patient-reported dyspnoea in COPD: BLAZE study. Eur Respir J. 2013. doi:10.1183/09031936.00124013.
26. Mahler DA, Decramer M, D'Urzo AD, et al. Superior lung function with once-daily QVA149 translates into improvements in patient-reported breathlessness compared with placebo and tiotropium In COPD patients: the BLAZE study [abstract P236 plus oral presentation]. American Thoracic Society 109th international conference; 17-22 May 2013; Philadelphia (PA).
27. Beeh KM, Korn S, Beier J, et al. Effect of QVA149 on lung volumes and exercise tolerance in COPD patients: the BRIGHT study. Respir Med. 2014. doi:10.1016/j.rmed.2014.01.006.
28. Novartis Pharmaceuticals. Effect of QVA149 on exercise tolerance in patients with chronic obstructive pulmonary disease (COPD) (BRIGHT) [ClinicalTrials.gov identifier NCT01294787]. US National Institutes of Health, ClinicalTrials.gov [online]. 2013. http://clinicaltrials.gov/show/NCT01294787. Accessed 9 Oct 2013.
29. Dahl R, Chapman KR, Rudolf M, et al. Safety and efficacy of dual bronchodilation with QVA149 in COPD patients: the ENLIGHTEN study. Respir Med. 2013;107(10):1558-67.
30. Banerji D, Alagappan V, Green Y, et al. Dual bronchodilation with once-daily QVA149 improves dyspnoea and health status and reduces symptoms and rescue medication use in patients with COPD: the IGNITE trials [poster]. European Respiratory Society 23rd Annual Congress; 7-11 Sep 2013; Barcelona.
31. Novartis Pharmaceuticals. A 52-week treatment, multi-center, randomized, double-blind, double dummy, parallel-group, active controlled study to compare the effect ofQVA149 (indacaterol maleate/glycopyrronium bromide) with salmeterol/fluticasone on the rate of exacerbations in subjects with moderate to very severe COPD (FLAME) [ClinicalTrials.gov identifier NCT01782326]. US National Institutes of Health, ClinicalTrials.gov [online]. 2013. http://clinicaltrials.gov/show/NCT01782326. Accessed 9 Oct 2013.
32. Vogelmeier CF, Bateman ED, Pallante J, et al. Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study. Lancet Respir Med. 2013;1(1):51-60.
33. Bateman ED, Vogelmeier C, Pallante J, et al. Once-daily QVA149 improves breathlessness and reduces rescue medication use compared to twice-daily salmeterol/fluticasone in patients with COPD: the ILLUMINATE study [abstract no. 807]. American Thoracic Society 109th international conference; 17-22 May 2013; Philadelphia (PA).
34. Dahl R, Gallagher N, Green Y, et al. QVA149 provides a rapid onset of action which is sustained throughout treatment in patients with COPD [poster]. European Respiratory Society 23rd Annual Congress; 7-11 Sep 2013; Barcelona.
35. Vogelmeier C, Dahl R, D'Urzo A, et al. Once-daily QVA149 provides clinically meaningful improvements in lung function and clinical outcomes [poster]. European Respiratory Society 23rd Annual Congress; 7-11 Sep 2013; Barcelona.
36. Barnes N, Hashimoto S, Nagase T, et al. QVA149 provides superior peak lung function in patients with COPD [poster]. European Respiratory Society 23rd Annual Congress; 7-11 Sep 2013; Barcelona.
37. Gallagher N, Alagappan V, Green Y, et al. Dual bronchodilation with once-daily QVA149 improves lung function and reduces exacerbations in patients with COPD: the IGNITE trials [poster]. European Respiratory Society 23rd Annual Congress; 7-11 Sep 2013; Barcelona.
38. Welte T, Dahl R, Chen H, et al. Once-daily QVA149 improves symptom scores in patients with COPD [poster]. European Respiratory Society 23rd Annual Congress; 7-11 Sep 2013; Barcelona.
39. Novartis Pharmaceuticals. A 26-week treatment randomized, double-blind, double dummy, parallel-group study to assess the efficacy, safety and tolerability of QVA149 (indacaterol/glycopyrronium bromide) compared to fluticasone/salmeterol in patients with moderate to severe chronic obstructive pulmonary disease [ClinicalTrials.gov identifier NCT01709903]. US National Institutes of Health, ClinicalTrials.gov [online]. 2013. http://clinicaltrials. gov/show/NCT01709903. Accessed 9 Oct 2013.
40. Novartis Pharmaceuticals. Comparison of long-term safety of the combination product QVA149A against placebo and standard of care treatment in chronic obstructive pulmonary disease patients with moderate to severe airflow limitation (RADIATE) [ClinicalTrials.gov identifier NCT01610037]. US National Institutes of Health, ClinicalTrials.gov [online]. 2013. http://clinicaltrials. gov/show/NCT01610037. Accessed 9 Oct 2013.
41. Bateman ED, Ferguson GT, Barnes N, et al. Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study. Eur Respir J. 2013;42(6):1484-94.
42. Welte T, Gallagher N, Green Y, et al. Dual bronchodilation with once-daily QVA149 provides significantly improved clinical outcomes versus mono-bronchodilator therapy: the SHINE study [abstract no. G25]. American Thoracic Society 109th international conference; 17-22 May 2013; Philadelphia (PA).
43. Bateman ED, Ferguson GT, Welte T, et al. Dual bronchodilation with once-daily QVA149 significantly improves lung function versus single bronchodilators and salmeterol/fluticasone [abstract no. G30]. American Thoracic Society 109th international conference; 17-22 May 2013; Philadelphia (PA).
44. Wedzicha JA, Decramer M, Ficker JH, et al. Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study. Lancet Respir Med. 2013;1(3):199-209.
45. Ficker J, Wedzicha JA, Decramer M, et al. QVA149 improves lung function and reduces exacerbations compared to tiotropium in patients with severe-to-very severe COPD: the SPARK study [poster]. European Respiratory Society 23rd Annual Congress; 7-11 Sep 2013; Barcelona.
46. Banerji D, Fowler Taylor A, Kho P, et al. Once-daily QVA149 provides superior improvements in lung function compared with glycopyrronium and tiotropium in severe COPD patients: a 52 week pooled analysis [poster]. European Respiratory Society 23rd Annual Congress; 7-11 Sep 2013; Barcelona.
47. Wedzicha JA, Decramer M, Vestbo J, et al. A novel study design for the comparison between once-daily QVA149 and twice-daily salmeterol/fluticasone on the reduction of COPD exacerbations: the FLAME study [poster]. European Respiratory Society 23rd Annual Congress; 7-11 Sep 2013; Barcelona.
48. Donohue JF. Minimal clinically important differences in COPD lung function. COPD. 2005;2:111-24. (Pubitemid 40776231)
49. Cazzola M, MacNee W, Martinez FJ, et al. Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur Respir J. 2008;31(2):416-69.
50. Jones PW, Beeh KM, Chapman KR, et al. Minimal clinically important differences in pharmacological trials. Am J Respir Crit Care Med. 2014;189(3):250-5.
51. Mahler DA, Witek TJ Jr. The MCID of the transition dyspnea index is a total score of one unit. COPD. 2005;2(1):99-103. (Pubitemid 40776229)
52. Jones PW. St George's Respiratory Questionnaire: MCID. COPD. 2005;2(1):75-9.
53. Welte T, Vogelmeier C, Dahl R, et al. Once-daily QVA149 has a good safety profile in patients with COPD [poster]. European Respiratory Society 23rd Annual Congress; 7-11 Sep 2013; Barcelona.
54. Ferguson GT, Barnes N, Mehta R, et al. Cardio- and cerebrovascular safety of QVA149: results from a pooled analysis [poster]. European Respiratory Society 23rd Annual Congress; 7-11 Sep 2013; Barcelona.
55. Chen H, D'Andrea P, Banerji D. QVA149 does not increase the risk of cardio- and cerebro-vascular events, pneumonia and exacerbation events compared with placebo: a network meta-analysis across multiple safety databases [poster]. European Respiratory Society 23rd Annual Congress; 7-11 Sep 2013; Barcelona.
56. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease (updated 2014). http://www.goldcopd.org/. Accessed 30 Jan 2014.
57. Gladysheva ES, Malhotra A, Owens RL. Influencing the decline of lung function in COPD: use of pharmacotherapy. Int J COPD. 2010;5:153-64.
58. Lemmens V, Oenema A, Knut IK, et al. Effectiveness of smoking cessation interventions among adults: a systematic review of reviews. Eur J Cancer Prev. 2008;17(6):535-44.
59. Ejiofor S, Turner AM. Pharmacotherapies for COPD. Clin Med Insights Circ Respir Pulm Med. 2013;7:17-34.
60. Qaseem A, Wilt TJ, Weinberger SE, et al. Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society. Ann Intern Med. 2011;155:179-91.
61. National Institute for Health and Clinical Excellence. CG101 Chronic obstructive pulmonary disease (updated): NICE guideline. http://guidance.nice. org.uk/CG101/NICEGuidance/pdf/English. Accessed 5 Dec 2013.
62. Spina D. Current and novel bronchodilators in respiratory disease. Curr Opin Pulm Med. 2014;20(1):73-86.
63. Tashkin DP, Ferguson GT. Combination bronchodilator therapy in the management of chronic obstructive pulmonary disease. Respir Res. 2013;14(1):49.
64. Montuschi P. Pharmacological treatment of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2006;1(4):409-23.
65. Boehringer Ingelheim. New once-daily Striverdi® (olodaterol) Respimat® gains approval in first EU countries [media release]. 18 Oct 2013. https://www.boehringer-ingelheim.com/news/news-releases/press-releases/2013/18- october-2013-olodaterol.html.
66. GlaxoSmithKline plc, and Theravance Inc. RELVAR® ELLIPTA® receives European marketing authorisation for the treatment of asthma and COPD [media release]. 18 Nov 2013. http://www.gsk.com/media/press-releases/2013/ relvar-ellipta-receives-european-marketing-authorisation-for-t.html.
67. Jacobsen JR, Choi SK, Combs J, et al. A multivalent approach to the discovery of long-acting β(2)-adrenoceptor agonists for the treatment of asthma and COPD. Bioorg Med Chem Lett. 2012;22(2):1213-8.
68. Bateman ED, Make BJ, Nandeuil MA. Safety and tolerability of a long-acting beta2-agonist in patients with COPD [abstract]. Am J Respir Crit Care Med. 2008;177:A653.
69. Aparici M, Gómez-Angelats M, Vilella D, et al. Pharmacological characterization of abediterol, a novel inhaled β(2)-adrenoceptor agonist with long duration of action and a favourable safety profile in preclinical models. J Pharmacol Exp Ther. 2012;342(2):497-509.
70. Fuso L, Mores N, Valente S, et al. Long-acting beta-agonists and their association with inhaled corticosteroids in COPD. Curr Med Chem. 2013;20(12):1477-95.
71. Woods JA, Nealy KL, Barrons RW. Aclidinium bromide: an alternative long-acting inhaled anticholinergic in the management of chronic obstructive pulmonary disease. Ann Pharmacother. 2013;47(7-8):1017-28.
72. Keam SJ, Keating GM. Tiotropium bromide. A review of its use as maintenance therapy in patients with COPD. Treat Respir Med. 2004;3(4):247-68. (Pubitemid 39263973)
73. Salmon M, Luttmann MA, Foley JJ, et al. Pharmacological characterization of GSK573719 (umeclidinium): a novel, long-acting, inhaled antagonist of the muscarinic cholinergic receptors for treatment of pulmonary diseases. J Pharmacol Exp Ther. 2013;345(2):260-70.
74. GlaxoSmithKline plc. GSK announces regulatory submission for umeclidinium monotherapy in European Union [media release]. 26 Apr 2013. http://www.gsk.com/media/press-releases/2013/GSK-announces-egulatory-ubmission- or-meclidinium-onotherapy-in-european-union.html.
75. GlaxoSmithKline plc, and Theravance Inc. GSK and Theravance announce regulatory submission for ANORO™ (UMEC/VI) in Europe [media release]. 8 Jan 2013. http://www.gsk.com/media/press-releases/2013/gsk-and-theravance- announce-regulatory-submission-for-anoro-umec-vi-in-europe.html.
76. Tashkin DP, Ferguson GT. Combination bronchodilator therapy in the management of chronic obstructive pulmonary disease. Respir Res. 2013. doi:10.1186/1465-9921-14-49.
77. Meurs H, Dekkers BG, Maarsingh H, et al. Muscarinic receptors on airway mesenchymal cells: novel findings for an ancient target. Pulm Pharmacol Ther. 2013;26(1):145-55.
78. Pera T, Zuidhof A, Valadas J, et al. Tiotropium inhibits pulmonary inflammation and remodelling in a guinea pig model of COPD. Eur Respir J. 2011;38:789-96.
79. Yu AP, Guérin A, Ponce de Leon D, et al. Therapy persistence and adherence in patients with chronic obstructive pulmonary disease: multiple versus single long-acting maintenance inhalers. J Med Econ. 2011;14(4):486-96.
80. Toy EL, Beaulieu NU, McHale JM, et al. Treatment of COPD: relationships between daily dosing frequency, adherence, resource use, and costs. Respir Med. 2011;105(3):435-41.
81. Roche N, Chanez P. Bronchodilator combinations for COPD: real hopes or a new Pandora's box? Eur Respir J. 2013;42:1441-5.
82. Schachter EN. Indacaterol/glycopyrronium bromide fixed-dose combination for the treatment of COPD. Drugs Today (Barc). 2013;49(7):437-46.
83. UK Medicines Information. New drugs online report for formoterol + glycopyrrolate. http://www.ukmi.nhs.uk/applications/ndo/record-view-open.asp? newDrugID=5371. Accessed 4 Dec 2013.
84. Almirall, S.A. Aclidinium and formoterol fixed dose combination for COPD submitted for registration in Europe [media release]. 4 November 2013. http://investors.almirall.es/phoenix.zhtml?c=209345&p=irol- newsArticle&ID=1871606&highlight=.
85. Cazzola M, Page C, Matera MG. Long-acting muscarinic receptor antagonists for the treatment of respiratory disease. Pulm Pharmacol Ther. 2013;26(3):307-17.
86. Dransfield MT, Bourbeau J, Jones PW, et al. Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomized controlled trials. Lancet Respir Med. 2013;1(3):210-23.
87. Cyr M-C, Beauchesne M-F, Lemière C, et al. Effects of inhaled corticosteroids in monotherapy or combined with long-acting β2-agonists on mortality among patients with chronic obstructive pulmonary disease. Ann Pharmacother. 2010;44(4):613-22.
88. GlaxoSmithKline. Seretide Diskus 50/100 microgram/dose inhalation powder, predispensed: EU summary of product characteristics. 2007. http://www.ema. europa.eu/docs/en-GB/document-library/Referrals-document/Seretide-Diskus-6-13/ WC500013534.pdf. Accessed 5 Dec 2013.
89. Astra Zeneca UK Ltd. Symbicort® Turbohaler® 100 micrograms/6 micrograms/inhalation, inhalation powder: summary of product characteristics. 2013. http://www.medicines.org.uk/emc/medicine/4820. Accessed 5 Dec 2013.
90. Tashkin DP, Doherty DE, Kerwin E, et al. Efficacy and safety characteristics of mometasone furoate/formoterol fumarate fixed-dose combination in subjects with moderate to very severe COPD: findings from pooled analysis of two randomized, 52-week placebo-controlled trials. Int J COPD. 2012;7:73-86.
91. Fuso L, Mores N, Valente S, et al. Long-acting beta-agonists and their association with inhaled corticosteroids in COPD. Curr Med Chem. 2013;20(12):1477-95.
92. Yang IA, Clarke MS, Sim EH, et al. Inhaled corticosteroids for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2012;7:CD002991.
93. Nannini LJ, Lasserson TJ, Poole P. Combined corticosteroid and long-acting beta(2)-agonist in one inhaler versus long-acting beta(2)-agonists for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2012;9:CD006829.
94. Anton E. How and when to use inhaled corticosteroids in chronic obstructive pulmonary disease? Expert Rev Respir Med. 2013;7(Suppl 2):25-32.
95. Thomas M, Radwan A, Stonham C, et al. COPD exacerbation frequency, pharmacotherapy and resource use: an observational study in UK primary care. COPD. 2013. doi:10.3109/15412555.2013.841671.
96. Novartis. Novartis data presented at ERS showcases once-daily COPD portfolio and further demonstrates efficacy of Ultibro® Breezhaler® (QVA149) [media release]. 8 Sep 2013. http://www.novartis.com/newsroom/media- releases/en/2013/1727858.shtml.
97. Rodrigo GJ, Nannini LJ, Rodriguez-Roisin R. Safety of long-acting beta-agonists in stable COPD: a systematic review. Chest. 2008;133(5):1079-87. (Pubitemid 351685509)
98. Wise RA, Anzueto A, Cotton D, et al. Tiotropium Respimat inhaler and the risk of death in COPD. New Engl J Med. 2013;369:1491-501.
99. Rutten-van Mölken MP. Goossens M. Cost effectiveness of pharmacological maintenance treatment for chronic obstructive pulmonary disease: a review of the evidence and methodological issues. Pharmacoeconomics. 2012;30(4):271-302.
100. Najafzadeh M, Marra CA, Sadatsafavi M, et al. Cost effectiveness of therapy with combinations of long acting bronchodilators and inhaled steroids for treatment of COPD. Thorax. 2008;63:962-7.